Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial
Vitamin K-dependent factors protect against vascular and renovascular calcification, and vitamin K antagonists may be associated with a decreased glomerular filtration rate (GFR). This study analyzed changes in GFR during long-term treatment with warfarin or dabigatran etexilate (DE) in patients enr...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
June 16, 2015
|
| In: |
Journal of the American College of Cardiology
Year: 2015, Jahrgang: 65, Heft: 23, Pages: 2481-2493 |
| ISSN: | 1558-3597 |
| DOI: | 10.1016/j.jacc.2015.03.577 |
| Online-Zugang: | Verlag, teilw. kostenfrei, Volltext: http://dx.doi.org/10.1016/j.jacc.2015.03.577 Verlag, teilw. kostenfrei, Volltext: http://www.sciencedirect.com/science/article/pii/S0735109715018562 
|
| Verfasserangaben: | Michael Böhm, MD; Michael D. Ezekowitz, MD, ChB, DPhil; Stuart J. Connolly, MD; John W. Eikelboom, MBBS; Stefan H. Hohnloser, MD; Paul A. Reilly, PhD; Helmut Schumacher, PhD; Martina Brueckmann, MD; Stephan H. Schirmer, MD, PhD; Mario T. Kratz, MD; Salim Yusuf, MD, DPhil; Hans-Christoph Diener, MD; Ziad Hijazi, MD; Lars Wallentin, MD, PhD |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1566408210 | ||
| 003 | DE-627 | ||
| 005 | 20240316100310.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 171214s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jacc.2015.03.577 |2 doi | |
| 035 | |a (DE-627)1566408210 | ||
| 035 | |a (DE-576)496408216 | ||
| 035 | |a (DE-599)BSZ496408216 | ||
| 035 | |a (OCoLC)1340983308 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Böhm, Michael |d 1958- |e VerfasserIn |0 (DE-588)1096256169 |0 (DE-627)856690694 |0 (DE-576)467967482 |4 aut | |
| 245 | 1 | 0 | |a Changes in renal function in patients with atrial fibrillation |b an analysis from the RE-LY trial |c Michael Böhm, MD; Michael D. Ezekowitz, MD, ChB, DPhil; Stuart J. Connolly, MD; John W. Eikelboom, MBBS; Stefan H. Hohnloser, MD; Paul A. Reilly, PhD; Helmut Schumacher, PhD; Martina Brueckmann, MD; Stephan H. Schirmer, MD, PhD; Mario T. Kratz, MD; Salim Yusuf, MD, DPhil; Hans-Christoph Diener, MD; Ziad Hijazi, MD; Lars Wallentin, MD, PhD |
| 264 | 1 | |c June 16, 2015 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 14.12.2017 | ||
| 520 | |a Vitamin K-dependent factors protect against vascular and renovascular calcification, and vitamin K antagonists may be associated with a decreased glomerular filtration rate (GFR). This study analyzed changes in GFR during long-term treatment with warfarin or dabigatran etexilate (DE) in patients enrolled in the RE-LY (Randomized Evaluation of Long Term Anticoagulation Therapy) trial. Of the 18,113 patients in the RE-LY study randomized to receive DE (110 mg or 150 mg twice daily) or warfarin, 16,490 patients with atrial fibrillation had creatinine values measured at baseline and at least 1 follow-up visit. Changes in GFR for up to 30 months were evaluated. GFR declined in all treatment groups. After an average of 30 months, the mean ± SE decline in GFR was significantly greater with warfarin (-3.68 ± 0.24 ml/min) compared with DE 110 mg (-2.57 ± 0.24 ml/min; p = 0.0009 vs. warfarin) and DE 150 mg (-2.46 ± 0.23 ml/min; p = 0.0002 vs. warfarin). A decrease in GFR >25% was less likely with DE 110 mg (hazard ratio: 0.81 [95% confidence interval: 0.69 to 0.96]; p = 0.017) or DE 150 mg (hazard ratio: 0.79 [95% confidence interval: 0.68 to 0.93]; p = 0.0056) than with warfarin in the observation period >18 months. Patients with poor international normalized ratio control (i.e., time in therapeutic range <65%) exhibited a faster decline in GFR. A more pronounced decline in GFR was associated with previous warfarin use and with the presence of diabetes. Patients with atrial fibrillation receiving oral anticoagulation exhibited a decline in renal function that was greater in those taking warfarin versus DE, and it was amplified by diabetes and previous vitamin K antagonist use. | ||
| 650 | 4 | |a anticoagulation | |
| 650 | 4 | |a atrial fibrillation | |
| 650 | 4 | |a renal function | |
| 650 | 4 | |a thrombin inhibition | |
| 650 | 4 | |a vitamin K antagonist | |
| 700 | 1 | |a Brückmann, Martina |d 1970- |e VerfasserIn |0 (DE-588)121145069 |0 (DE-627)705257290 |0 (DE-576)292557736 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |a American College of Cardiology |t Journal of the American College of Cardiology |d New York, NY : Elsevier, 1983 |g 65(2015), 23, Seite 2481-2493 |h Online-Ressource |w (DE-627)266884717 |w (DE-600)1468327-1 |w (DE-576)099603837 |x 1558-3597 |7 nnas |
| 773 | 1 | 8 | |g volume:65 |g year:2015 |g number:23 |g pages:2481-2493 |g extent:13 |a Changes in renal function in patients with atrial fibrillation an analysis from the RE-LY trial |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jacc.2015.03.577 |x Verlag |x Resolving-System |z teilw. kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0735109715018562 |x Verlag |z teilw. kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20171214 | ||
| 993 | |a Article | ||
| 994 | |a 2015 | ||
| 998 | |g 121145069 |a Brückmann, Martina |m 121145069:Brückmann, Martina |d 60000 |e 60000PB121145069 |k 0/60000/ |p 8 | ||
| 999 | |a KXP-PPN1566408210 |e 2990014691 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title":"Changes in renal function in patients with atrial fibrillation","subtitle":"an analysis from the RE-LY trial","title_sort":"Changes in renal function in patients with atrial fibrillation"}],"person":[{"role":"aut","given":"Michael","roleDisplay":"VerfasserIn","display":"Böhm, Michael","family":"Böhm"},{"role":"aut","given":"Martina","display":"Brückmann, Martina","family":"Brückmann","roleDisplay":"VerfasserIn"}],"note":["Gesehen am 14.12.2017"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"physDesc":[{"extent":"13 S."}],"language":["eng"],"id":{"doi":["10.1016/j.jacc.2015.03.577"],"eki":["1566408210"]},"recId":"1566408210","relHost":[{"part":{"pages":"2481-2493","volume":"65","issue":"23","extent":"13","text":"65(2015), 23, Seite 2481-2493","year":"2015"},"corporate":[{"display":"American College of Cardiology","roleDisplay":"VerfasserIn","role":"aut"}],"origin":[{"publisherPlace":"New York, NY ; New York, NY","dateIssuedKey":"1983","publisher":"Elsevier ; American College of Cardiology","dateIssuedDisp":"1983-"}],"disp":"American College of CardiologyJournal of the American College of Cardiology","pubHistory":["1.1983 -"],"note":["Gesehen am 13.11.25","Ungezählte Beil.: Supplement"],"title":[{"title_sort":"Journal of the American College of Cardiology","subtitle":"JACC","title":"Journal of the American College of Cardiology"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"id":{"eki":["266884717"],"issn":["1558-3597"],"zdb":["1468327-1"]},"physDesc":[{"extent":"Online-Ressource"}],"recId":"266884717","titleAlt":[{"title":"JACC"}]}],"name":{"displayForm":["Michael Böhm, MD; Michael D. Ezekowitz, MD, ChB, DPhil; Stuart J. Connolly, MD; John W. Eikelboom, MBBS; Stefan H. Hohnloser, MD; Paul A. Reilly, PhD; Helmut Schumacher, PhD; Martina Brueckmann, MD; Stephan H. Schirmer, MD, PhD; Mario T. Kratz, MD; Salim Yusuf, MD, DPhil; Hans-Christoph Diener, MD; Ziad Hijazi, MD; Lars Wallentin, MD, PhD"]},"origin":[{"dateIssuedDisp":"June 16, 2015","dateIssuedKey":"2015"}]} | ||
| SRT | |a BOEHMMICHACHANGESINR1620 | ||